Advertisement
Dr. Rosskamp commented, "Deborah and Steven are valuable additions to ourR&D team. Deborah brings with her extensive clinical experience in thecritical care setting and a deep understanding of the crucial role of MedicalAffairs in developing and maintaining relationships with our most influentialcustomers. In addition, she has forged strong professional relationships inthe Pulmonary and Endocrine Community and worked closely with the clinicalteams on sponsor-initiated Phase 3b/4 studies.
Advertisement
"Steven has a proven track-record of successful interactions withregulatory authorities worldwide and has been an accomplished team player onmany company project teams and inter-company alliance teams. He hassignificant expertise in regulatory due-diligence activities, which will helpus to identify promising in-licensing candidates for Ikaria. I look forward toworking with both Deborah and Steven as we continue to move our developmentpipeline forward."
Daniel Tasse, President & CEO of Ikaria, remarked, "Because we have adeep, very active product pipeline, it is vital that we have strong Medicaland Regulatory Affairs teams in place. Deborah and Steve bring a wealth ofexperience in their respective areas of expertise to the R&D team, and we arevery pleased that they have elected to join Ikaria. I am certain that theywill provide strong leadership as we endeavor to expand the indications forINOmax, progress our clinical pipeline, and capitalize on Ikaria's mission todevelop novel treatments for the critically ill in the in-hospital and ICUsetting."
Dr. Petrowsky was previously World Wide Medical Director, Medical Affairsat Pfizer in New York, where she was responsible for the medical approval ofall product promotional materials, marketing and sales, as well as publicationstrategies for the brands Exubera, Revatio (a drug for pulmonary hypertension)and Chantix. Prior to joining Pfizer, she practiced as a Pulmonary/CriticalCare Specialist in both hospital and private practice. Dr. Petrowsky receivedher MD from UMDNJ -- New Jersey Medical School and is Board Certified inInternal Medicine, Pulmonary Disease and Critical Care. She completed aFellowship in Pulmonary and Critical Care Medicine at the Hahnemann Divisionof Allegheny University Hospital in Philadelphia, PA.
Dr. Knapp brings over 20 years of regulatory experience in all phases ofdrugs, biologics, diagnostics, devices and cosmetics. He most recently was theVice President of Global Regulatory Affairs of Par Pharmaceuticals, BrandedDivision, and prior to that he spent 13 years at Bristol-Myers-Squibb, wherehis most recently held position was Executive Director, Global RegulatoryStrategy. Previously, he held positions of increasing importance at Schering-Plough. Dr. Knapp began his career as Product Development Scientist at Johnson& Johnson Research, Janssen Pharmaceuticals. He holds a M.S. in PharmaceuticalEngineering from Rutgers College of Pharmacy and Engineering and a Pharm.D.from Rutgers College of Pharmacy.
About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a fully integrated biotherapeutics companyfocused on the development and commercialization of innovative pharmaceuticaland biological products and drug/device combinations for the critically ill inthe hospital and ICU setting. The company's product, INOmax(R) (nitric oxide)for inhalation, is an FDA-approved drug for the treatment of hypoxicrespiratory failure i